| MRP | : |
|
| Price | : | ₹8,950.00 |
| You Save | : | ₹55,045.00Â (86.01%) |
1 Vial(s) Of 16ml
Bryxta 400mg Injection is an anticancer medication that contains Bevacizumab as its active ingredient. This treatment is designed to inhibit tumor growth. It is prescribed in conjunction with other chemotherapy drugs for the management of metastatic breast cancer, brain cancer, cervical cancer, kidney cancer, lung cancer, and colorectal cancer. Additionally, it is utilized for treating ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Effective birth control should be employed during treatment and for at least six months following the final dose. Bryxta 400mg Injection is not suitable for adolescents and children under 18 years of age. If you are considering pregnancy soon, consult your doctor regarding ovarian preservation, as this medication may lead to fertility issues in women. It is advisable to refrain from breastfeeding, as this drug may affect the growth and development of your baby.
Bryxta 400mg Injection is frequently given in combination with other chemotherapy medications. Common side effects include constipation, loss of appetite, runny nose, fever, skin issues, and weight loss. Prior to commencing treatment with this medication, inform your doctor if you have high blood pressure, elevated blood sugar, gastrointestinal disorders, or heart conditions. This medication should not be administered for 28 days before or after any surgical procedures due to its association with poor wound healing and increased bleeding risks. It is recommended to notify your doctor of any dental problems requiring surgery before starting this medication. Should you experience any changes in vision or confusion, contact your doctor immediately to avoid complications.
Bryxta 400mg Injection is prescribed for the treatment of the following conditions:
Glioblastoma multiforme (a type of brain cancer)
Persistent, recurrent, or metastatic breast cancer
Metastatic cervical cancer
Advanced kidney cancer
Metastatic colorectal cancer
Advanced non-small-cell lung cancer
Liver cancer - specifically hepatocellular carcinoma
Cancers affecting the ovary, cervical region, fallopian tube, or primary peritoneal cancer
Bryxta 400mg Injection is a humanized monoclonal antibody that has been engineered to function as a targeted treatment for several advanced cancers. It exerts its effects by specifically attaching to a protein known as vascular endothelial growth factor A (VEGF-A), which is found in the lining of blood and lymphatic vessels throughout the body. This action disrupts the interaction between VEGF-A and its receptors, thereby preventing the development of blood vessels that deliver oxygen and nutrients to tumors. Consequently, it reduces the speed at which cancer progresses.
Notify your physician of any prescribed drugs, over-the-counter medications, nutritional and vitamin supplements, as well as herbal products you are currently taking or have previously taken prior to the treatment. Some medications may interact with Bryxta 400mg Injection and lead to unwanted side effects.
Your doctor or nurse will provide Bryxta 400mg Injection through an intravenous infusion. The infusion must be administered right after the dilution.
Store Bryxta 400mg Injection between 2ËšC and 8ËšC. Avoid freezing or shaking.
Shield from light. Keep away from children.
Adverse effects are undesired symptoms resulting from medications. While all medications can lead to side effects, not everyone experiences them.
Serious:
Headache
Vision alterations
Disorientation
Severe allergic reactions
Elevated blood pressure
Delayed healing of surgical wounds
Presence of protein in urine
Severe infections
Blood clots in arteries and pulmonary blood vessels
Perforation of the gut
Nosebleeds and increased bleeding risk
Cardiac issues with elevated heart rate
Mouth ulcers, dryness
Difficulty breathing
Common:
Tingling in hands or feet
Fatigue and lack of energy
Diarrhea, nausea, vomiting, stomach pain
Constipation
Decreased appetite
Weight reduction
Alterations in taste and speech
Reduction in white blood cell counts
Fever
Dry skin
Lower back pain
Molecule Name: BEVACIZUMAB
Therapeutic Class: Anticancer
Pharmacological Class: VEGF Inhibitor
At Medfast, we’re dedicated to bringing you accurate, trustworthy, and expert-vetted health information. Our primary goal is to ensure you receive content that you can rely on.
It’s crucial to understand that everything on this website is for general information purposes only. This content is not a substitute for professional medical advice, diagnosis, or treatment. We can’t stress enough the importance of consulting with your own doctor. They are the only ones who can provide tailored advice for your specific health concerns or medication questions.
Please, never ignore or delay seeking professional medical advice because of something you’ve read here. Our fundamental mission is to support and enhance the doctor-patient relationship, not to replace it.
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.
100% secure and trusted payment protection
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.
